Lithium response in bipolar disorder: No difference in GADL1 gene expression between cell lines from excellent-responders and non-responders

Jeverson Moreira; Cindie Courtin; Pierre A Geoffroy; Emmanuel Curis; Frank Bellivier; Cynthia Marie-Claire

doi:10.1016/j.psychres.2017.02.022

Lithium response in bipolar disorder: No difference in GADL1 gene expression between cell lines from excellent-responders and non-responders

Psychiatry Res. 2017 May:251:217-220. doi: 10.1016/j.psychres.2017.02.022. Epub 2017 Feb 14.

Authors

Jeverson Moreira¹, Cindie Courtin², Pierre A Geoffroy³, Emmanuel Curis⁴, Frank Bellivier³, Cynthia Marie-Claire⁵

Affiliations

¹ Inserm, U1144, Paris F-75006, France; Université Sorbonne Paris Cité, UMR-S 1144, Paris F-75006, France. Electronic address: jeverson.moreira@inserm.fr.
² Inserm, U1144, Paris F-75006, France; Université Sorbonne Paris Cité, UMR-S 1144, Paris F-75006, France.
³ Inserm, U1144, Paris F-75006, France; Université Sorbonne Paris Cité, UMR-S 1144, Paris F-75006, France; AP-HP, GH Saint-Louis - Lariboisière - F. Widal, Pôle de Psychiatrie et de Médecine Addictologique, 75475 Paris cedex 10, France; Fondation FondaMental, Créteil, 94000, France.
⁴ Inserm, U1144, Paris F-75006, France; Université Sorbonne Paris Cité, UMR-S 1144, Paris F-75006, France; Département de Biostatistique et Informatique Médicale, Hôpital Saint-Louis, APHP, Paris, France; Laboratoire de biomathématiques, plateau iB(2), Faculté de pharmacie de Paris, France.
⁵ Inserm, U1144, Paris F-75006, France; Université Sorbonne Paris Cité, UMR-S 1144, Paris F-75006, France. Electronic address: cynthia.marie-claire@parisdescartes.fr.

PMID: 28214779
DOI: 10.1016/j.psychres.2017.02.022

Abstract

Previous association studies have shown mixed results between glutamic acid decarboxylase like-1 (GADL1) gene polymorphism and prophylactic lithium response in bipolar disorder (BD) patients. In the present study, GADL1 gene expression was investigated in regard to lithium response, using Alda scale, in lymphoblastoid cells (LCLs) of 36 Caucasian BD patients. No difference in GADL1 expression was observed among LCLs from excellent-responders, non-responders or controls. Furthermore, lithium did not induce significant changes in GADL1 expression levels after 4 or 8 days. These results did not support an association of GADL1 expression in the determination of a lithium response in BD patients.

Keywords: Biomarker; Mood disorder; Therapeutic response.

MeSH terms

Adult
Antimanic Agents / pharmacology*
Bipolar Disorder / drug therapy*
Bipolar Disorder / genetics*
Carboxy-Lyases / genetics*
Carboxy-Lyases / metabolism
Cell Line
Female
Gene Expression / drug effects*
Humans
Lithium Compounds / pharmacology*
Male
Middle Aged
Polymorphism, Genetic
Treatment Outcome

Substances

Antimanic Agents
Lithium Compounds
Carboxy-Lyases
GADL1 protein, human